StockData
Interpace Biosciences, Inc. logo

Interpace Biosciences, Inc. (IDXG) shareholders

IDXGOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/30
$5.00−0.15 (-2.91%)

Close on Oct 19, 2026Market cap $138.57MP/E 5.6Yield –

Ownership

Who owns Interpace Biosciences's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
AMP-18 Management Company Limited Partnership
Joint filing with Ampersand 2018 Limited Partnership (76.00%), Amp-18 Mc LLC (76.00%)
13,861,38676.00%13D (active) amendmentOct 11, 2024
1315 Capital II, L.P.
Joint filing with 1315 Capital Management II, LLC (68.00%)
9,405,94068.00%13D (active) amendmentOct 11, 2024
Douglas M. Singer227,0465.15%13G (passive) amendmentDec 31, 2024

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Thomas W. BurnellCEO, President & Chairman, Director2,048,5307.40%Aug 20, 2026
Christopher McCarthyCFO & COO323,8001.17%Aug 20, 2026
Stephen J. SullivanDirector24,5830.09%Aug 20, 2026
Vijay AggarwalDirector––Aug 20, 2026
Joseph D. KeeganDirector17,5690.06%Aug 20, 2026
Fortunato R. RoccaDirector––Aug 20, 2026
1315 Capital II, L.P.10% owner9,405,94133.96%Feb 17, 2026
2018 Limited Partnership Ampersand10% owner13,861,38650.04%Feb 4, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Christopher McCarthy
CFO & COO
Aug 20, 2026Option exercise+277,009––323,800
Thomas W. Burnell
CEO, President & Chairman, Director
Aug 20, 2026Option exercise+1,966,763––2,037,645
Thomas W. Burnell
CEO, President & Chairman, Director
Aug 20, 2026Tax withholding−581,718$1.61$936.57K1,455,927
1315 Capital II, L.P.
10% owner
Jan 20, 2026Conversion+9,405,941$2.02$19.00M9,405,941
2018 Limited Partnership Ampersand
10% owner
Jan 20, 2026Conversion+13,861,386$2.02$28.00M13,861,386
Christopher McCarthy
Chief Financial Officer
Dec 1, 2024Option exercise+1,111––46,791
Christopher McCarthy
Chief Financial Officer
Jul 27, 2024Option exercise+15,112––45,680
Christopher McCarthy
Chief Financial Officer
Feb 1, 2024Option exercise+6,045––30,568
Christopher McCarthy
Chief Financial Officer
Feb 1, 2024Award+10,000––45,644
Christopher McCarthy
Chief Financial Officer
Jan 31, 2024Option exercise+7,556––24,523
Christopher McCarthy
Chief Financial Officer
Dec 1, 2023Option exercise+1,095––16,967
Christopher McCarthy
Chief Financial Officer
Jul 31, 2023Option exercise+7,556––15,872
Christopher McCarthy
Chief Financial Officer
Jul 31, 2023Award+25,000––35,644
Thomas W. Burnell
President & CEO, Director
May 21, 2021Buy+10,855$8.68$94.22K10,855
Thomas John Freeburg
Chief Financial Officer
Mar 10, 2021Award+50,000––52,000
Peter Kamin
10% owner
Mar 1, 2021Buy+8,252$3.08$25.42K133,186
Peter Kamin
10% owner
Mar 1, 2021Buy+2,862$3.08$8.81K44,670
Peter Kamin
10% owner
Mar 1, 2021Buy+14,726$3.08$45.36K234,805
Peter Kamin
10% owner
Mar 1, 2021Buy+16,360$3.08$50.39K270,108
Peter Kamin
10% owner
Feb 26, 2021Buy+2,897$3.17$9.18K41,808
Peter Kamin
10% owner
Feb 26, 2021Buy+8,333$3.17$26.42K124,934
Peter Kamin
10% owner
Feb 26, 2021Buy+14,946$3.17$47.38K253,748
Peter Kamin
10% owner
Feb 26, 2021Buy+14,874$3.17$47.15K220,079
Robert J. Gorman
Director
Jan 29, 2021Award+12,438$4.02$50.00K18,759
Thomas W. Burnell
President and CEO, Director
Dec 1, 2020Award+125,000––225,000
Thomas W. Burnell
President and CEO, Director
Dec 1, 2020Award+100,000––225,000
James Early
–
Jul 29, 2020Option exercise+5,000––7,125
Jack E. Stover
President and CEO, Director
Mar 12, 2020Award+7,188––30,271
Robert J. Gorman
Director
Jan 29, 2020Award+6,321$7.91$50.00K6,321
Gregory Richard
Chief Commerical Officer
Mar 13, 2019Award+39,528––84,169
James Early
Chief Financial Officer
Mar 13, 2019Award+26,340––43,340
Jack E. Stover
President and CEO, Director
Mar 13, 2019Award+86,922––427,300
Thomas John Freeburg
Chief Accounting Officer
Mar 13, 2019Award+2,000––2,000
Jack E. Stover
President and CEO, Director
Dec 5, 2018Award+87,000––340,378
Gregory Richard
Chief Commerical Officer
Dec 5, 2018Award+13,400––44,641
James Early
Chief Financial Officer
Dec 5, 2018Award+3,000––17,000
Jack E. Stover
President and CEO, Director
Dec 5, 2018Award+60,000––313,378
Joseph D. Keegan
Director
Mar 7, 2018Award+4,800––17,569
Stephen J. Sullivan
Director
Mar 7, 2018Award+4,800––24,583
Gregory Richard
Chief Commerical Officer
Mar 7, 2018Award+28,000––31,241
James Early
Chief Financial Officer
Mar 7, 2018Award+14,000––14,000
Jack E. Stover
President and CEO, Director
Mar 7, 2018Award+56,000––75,738
Felice Schnoll-Sussman
Director
Mar 7, 2018Award+4,800––4,800
Gregory Richard
Chief Commerical Officer
Feb 26, 2018Option exercise+2,000––3,241
Harry Glorikian
Director
Feb 3, 2016Award+127,696$0.47$60.02K127,696
Joseph D. Keegan
Director
Feb 3, 2016Award+127,696$0.47$60.02K127,696
Stephen J. Sullivan
Director
Feb 3, 2016Award+100,000$0.47$47.00K197,828
Jack E. Stover
Interim President and CEO, Director
Feb 3, 2016Award+100,000$0.53$53.00K197,378
Graham G. Miao
CFO
Dec 28, 2015Tax withholding−69,020$0.53$36.58K142,852
Gerald R. Melillo JR
President, Sales Services
Dec 1, 2015Sale−1,748$0.77$1.35K130,173
Gerald R. Melillo JR
President, Sales Services
Nov 30, 2015Sale−765$0.80$612131,921
Gerald R. Melillo JR
President, Sales Services
Nov 25, 2015Sale−4,262$0.78$3.32K132,686
Gerald P. Belle
Director
Jun 3, 2015Award+45,455$1.32$60.00K120,686
John Federspiel
Director
Jun 3, 2015Award+34,091$1.32$45.00K100,378
Heinrich Dreismann
Director
Jun 3, 2015Award+34,091$1.32$45.00K50,177
Jack E. Stover
Director
Jun 3, 2015Award+34,091$1.32$45.00K97,378
Stephen J. Sullivan
Director
Jun 3, 2015Award+34,091$1.32$45.00K97,828
Gerald P. Belle
Director
Jun 3, 2015Award+45,455$1.32$60.00K143,086
Nancy Lurker
CEO, Director
Mar 5, 2015Award+444,364$1.73$768.75K871,681
Gerald R. Melillo JR
President, Sales Services
Feb 24, 2015Award+91,217$1.85$168.75K136,948

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
+550.0%
From 0M shares
Short volume, 0 days
–
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Interpace Biosciences's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.

See a number that looks wrong?